share_log

Pfizer | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC(4.96%)

Pfizer | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC(4.96%)

輝瑞 | SC 13G/A：超過5%持股股東披露文件(修正)-PFIZER INC(4.96%)
SEC announcement ·  03/15 19:50
牛牛AI助理已提取核心訊息
Pfizer Inc., a pharmaceutical giant incorporated in Delaware, has filed an exit filing with the United States Securities and Exchange Commission (SEC) on January 29, 2024, indicating that it no longer holds more than 5% of Tourmaline Bio, Inc.'s common stock. The filing, made under Rule 13d-1(c) of the Securities Exchange Act of 1934, shows that Pfizer Inc. beneficially owns 1,272,214 shares of Tourmaline Bio's common stock, which represents 4.96% of the company's class of securities. This percentage is based on 25,645,262 shares of common stock outstanding as disclosed by Tourmaline Bio in its prospectus supplement filed on January 26, 2024. The address of Pfizer's principal business office is 66 Hudson Boulevard East, New York, NY, and the CUSIP number for the securities is 89157D 105. Pfizer's filing confirms that the shares were not acquired for the purpose of changing or influencing the control of Tourmaline Bio and were not held in connection with any transaction having that purpose or effect.
Pfizer Inc., a pharmaceutical giant incorporated in Delaware, has filed an exit filing with the United States Securities and Exchange Commission (SEC) on January 29, 2024, indicating that it no longer holds more than 5% of Tourmaline Bio, Inc.'s common stock. The filing, made under Rule 13d-1(c) of the Securities Exchange Act of 1934, shows that Pfizer Inc. beneficially owns 1,272,214 shares of Tourmaline Bio's common stock, which represents 4.96% of the company's class of securities. This percentage is based on 25,645,262 shares of common stock outstanding as disclosed by Tourmaline Bio in its prospectus supplement filed on January 26, 2024. The address of Pfizer's principal business office is 66 Hudson Boulevard East, New York, NY, and the CUSIP number for the securities is 89157D 105. Pfizer's filing confirms that the shares were not acquired for the purpose of changing or influencing the control of Tourmaline Bio and were not held in connection with any transaction having that purpose or effect.
輝瑞公司是一家在特拉華州註冊成立的製藥巨頭，已於2024年1月29日向美國證券交易委員會（SEC）提交了退出申請，表示其持有的不再超過Tourmaline Bio, Inc.5％的股份。”s 普通股。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，顯示輝瑞公司實益擁有Tourmaline Bio普通股的1,272,214股，佔該公司證券類別的4.96％。該百分比基於Tourmaline Bio在2024年1月26日提交的招股說明書補充文件中披露的25,645,262股已發行普通股。輝瑞主要營業辦公室的地址是紐約州紐約哈德遜大道東66號，證券的CUSIP號碼爲89157D 105。輝瑞的文件證實，收購這些股份不是爲了改變或影響Tourmaline Bio的控制權，也不是與任何具有該目的或效果的交易有關而持有的。
輝瑞公司是一家在特拉華州註冊成立的製藥巨頭，已於2024年1月29日向美國證券交易委員會（SEC）提交了退出申請，表示其持有的不再超過Tourmaline Bio, Inc.5％的股份。”s 普通股。該文件是根據1934年《證券交易法》第13d-1（c）條提交的，顯示輝瑞公司實益擁有Tourmaline Bio普通股的1,272,214股，佔該公司證券類別的4.96％。該百分比基於Tourmaline Bio在2024年1月26日提交的招股說明書補充文件中披露的25,645,262股已發行普通股。輝瑞主要營業辦公室的地址是紐約州紐約哈德遜大道東66號，證券的CUSIP號碼爲89157D 105。輝瑞的文件證實，收購這些股份不是爲了改變或影響Tourmaline Bio的控制權，也不是與任何具有該目的或效果的交易有關而持有的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。